Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (the "Company") on June 28, 2018. The Company is an emerging growth company incorporated in Delaware. The report details a material definitive agreement entered into on the same date by Napo Pharmaceuticals, Inc., a wholly-owned subsidiary of the Company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a new commercial agreement rather than reporting period financial results.
Material Changes and Agreements
On June 28, 2018, Napo Pharmaceuticals, Inc. entered into a definitive co-promotion agreement with RedHill Biopharma Ltd. ("RedHill"). Key terms include:
- Scope: RedHill received the exclusive right to co-promote Mytesi, Napo's FDA-approved drug, to gastroenterologists and primary care physicians in the United States for its current approved indication.
- Compensation: Napo will pay RedHill a specified amount per unit of product dispensed.
- Intellectual Property: Napo granted RedHill a royalty-free right to use trademarks and copyrights related to Mytesi for promotion purposes in the U.S.
- Governance: A joint promotion committee composed of representatives from both parties will supervise and manage the co-promotion activities.
- Term: The agreement expires on December 28, 2018, unless extended by mutual agreement.
Outlook, Risks, and Termination Provisions
The agreement includes specific termination rights and risks:
- Termination for Convenience: RedHill may terminate the agreement, in whole or in part, at any time upon 30 days' prior written notice.
- Termination for Cause: Either party may terminate for material breach, violation of law (if uncured), bankruptcy, insolvency, dissolution, or regulatory action against the other party.
- Reversion of Rights: Upon expiration or termination, all rights granted to RedHill automatically terminate and revert to Napo.
- Confidentiality: Portions of the full agreement text are subject to a request for confidential treatment and will be filed with the Company's Form 10-Q for the quarter ending June 30, 2018.
Investor Verification Checklist
- Verify the specific "amount per unit" payment terms in the full agreement text filed as an exhibit to the Form 10-Q.
- Monitor the performance of the joint promotion committee and the impact on Mytesi sales volume.
- Assess the risk of early termination by RedHill given the 30-day notice provision for convenience.
- Review the upcoming Form 10-Q for the quarter ending June 30, 2018, for the complete agreement text and any financial impact disclosures.